DUBLIN, Ireland, Nov. 12, 2015 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, is pleased to provide an update on its Animal Health Symposium, which is being held from 10:30AM to 12:30PM ET on Monday, November 23rd, 2015 at Le Parker Meridien Hotel in New York, NY.
A key opinion leader (KOL) forum intended to provide investors and analysts with an educational experience on the unmet needs in the companion animal health sector, will be the focal point of this event. The keynote address will be presented by Dr. George Gunn, Former Division Head of Novartis Animal Health and a former member of the Novartis Executive Committee.
Featured key opinion leaders include Dr. Duncan Lascelles, Prof. of Surgery and Pain Management at North Carolina State University who will focus on pain management in dogs and cats. In addition, veterinarians representing large, specialty and small clinics will form a panel moderated by banking analysts, addressing challenges and opportunities facing their respective practices.
- Dr. Gary Holfinger, South Suburban Animal Hospital, Perrysburg, OH
- Dr. Elizabeth Orcutt, Red Bank Veterinary Hospital, Tinton Falls, NJ
- Dr. Jerry Wilson, Animal Hospital of Colin County, Allen, TX
- Kevin Ellich, Principal and Senior Research Analyst at Piper Jaffray & Co.
- Kathy Minor, Vice President Research, Cowen and Company
- Erin Wilson, Research Analyst, Bank of America Merrill Lynch Global Research
As part of the forum, Nexvet will showcase its transformational PETization™ platform, which creates 100% species-specific monoclonal antibodies (mAbs), areas of further therapeutic focus, and provide an update on the Company's lead programs, which address pain in dogs and cats.
To register for this event, please send an email request to IR@nexvet.com with your name, company and phone number. Le Parker Meridien Hotel is located at 119 West 56th Street, New York, N.Y. 10019-3318.
About Nexvet (www.nexvet.com)
Nexvet is a veterinary biologics developer focused on transforming the therapeutic market for companion animals, such as dogs and cats, by developing and commercializing novel, species-specific biologics. Nexvet's proprietary PETization™ platform is designed to rapidly create monoclonal antibodies ("mAbs") that are recognized as "self" or "native" by an animal's immune system, a property Nexvet refers to as "100% species-specificity." Nexvet's product candidates also build upon the safety and efficacy data from clinically tested human therapies, thereby reducing clinical risk and development cost.
Nexvet is leveraging diverse global expertise and incentives to build a vertically integrated biopharmaceutical company, through conducting drug discovery in Australia, clinical development in the United States and biomanufacturing in Ireland.
CONTACT: Investors Candice Knoll Blueprint Life Science Group +1 415-375-3340 Ext. 4 firstname.lastname@example.org Media David Salisbury Berry & Company Public Relations +1 212-253-8881 email@example.com
Source:Nexvet Biopharma plc